You are here: Home » Reuters » News
Business Standard

Delhi High Court quashes government ban on 344 drugs after industry petitions

Reuters  |  NEW DELHI 

By Suchitra Mohanty and Zeba Siddiqui

(Reuters) - stayed on Thursday a ban on 344 drugs that it deemed lacked therapeutic efficacy, after over six months of hearing more than 300 petitions filed by drugmakers against it.

Sanjay Jain, a lawyer representing the central government, told Reuters the was evaluating the decision and planned to appeal at a higher court. The exact reasons for the stay are not yet known, as the order has not been made public yet, but is expected to be uploaded on the website.

Thursday's decision provides interim relief to several local and multinational drugmakers operating in India's $15 billion drugs industry whose business had been hit by the ban. Many, however, had obtained stay orders days after the ban was announced in March.

The move covered fixed-dose combination drugs, which are cocktails of medicines that are used worldwide to improve patients' compliance in complicated courses of treatment, especially for conditions such as HIV, tuberculosis and malaria.

In India, however, lax regulation and inconsistent enforcement of laws has led to many such drugs entering the market without central approval, a Reuters investigation found last year. Roughly half the drugs sold on the Indian market are combination medicines, including many antibiotics, the misuse of which leads to antibiotic resistance. (http://reut.rs/1J9azFo)

The announced the ban in March saying extensive deliberations with scientific experts had found the medicines lacked therapeutic efficacy. (http://reut.rs/2gKUfo2)

Most companies filed petitions arguing the did not exercise its powers appropriately.

The reversal of the ban means companies can continue to sell these drugs.

The decision is another setback for India's efforts to weed out irrational fixed-dose combination drugs from the market. A similar move in 2007 to ban about 294 such drugs was also met with stiff resistance from the industry, which obtained a stay.

(Writing by Zeba Siddiqui; Editing by Muralikumar Anantharaman)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

RECOMMENDED FOR YOU

Delhi High Court quashes government ban on 344 drugs after industry petitions

NEW DELHI (Reuters) - Delhi High Court stayed on Thursday a government ban on 344 drugs that it deemed lacked therapeutic efficacy, after over six months of hearing more than 300 petitions filed by drugmakers against it.

By Suchitra Mohanty and Zeba Siddiqui

(Reuters) - stayed on Thursday a ban on 344 drugs that it deemed lacked therapeutic efficacy, after over six months of hearing more than 300 petitions filed by drugmakers against it.

Sanjay Jain, a lawyer representing the central government, told Reuters the was evaluating the decision and planned to appeal at a higher court. The exact reasons for the stay are not yet known, as the order has not been made public yet, but is expected to be uploaded on the website.

Thursday's decision provides interim relief to several local and multinational drugmakers operating in India's $15 billion drugs industry whose business had been hit by the ban. Many, however, had obtained stay orders days after the ban was announced in March.

The move covered fixed-dose combination drugs, which are cocktails of medicines that are used worldwide to improve patients' compliance in complicated courses of treatment, especially for conditions such as HIV, tuberculosis and malaria.

In India, however, lax regulation and inconsistent enforcement of laws has led to many such drugs entering the market without central approval, a Reuters investigation found last year. Roughly half the drugs sold on the Indian market are combination medicines, including many antibiotics, the misuse of which leads to antibiotic resistance. (http://reut.rs/1J9azFo)

The announced the ban in March saying extensive deliberations with scientific experts had found the medicines lacked therapeutic efficacy. (http://reut.rs/2gKUfo2)

Most companies filed petitions arguing the did not exercise its powers appropriately.

The reversal of the ban means companies can continue to sell these drugs.

The decision is another setback for India's efforts to weed out irrational fixed-dose combination drugs from the market. A similar move in 2007 to ban about 294 such drugs was also met with stiff resistance from the industry, which obtained a stay.

(Writing by Zeba Siddiqui; Editing by Muralikumar Anantharaman)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Delhi High Court quashes government ban on 344 drugs after industry petitions

By Suchitra Mohanty and Zeba Siddiqui

(Reuters) - stayed on Thursday a ban on 344 drugs that it deemed lacked therapeutic efficacy, after over six months of hearing more than 300 petitions filed by drugmakers against it.

Sanjay Jain, a lawyer representing the central government, told Reuters the was evaluating the decision and planned to appeal at a higher court. The exact reasons for the stay are not yet known, as the order has not been made public yet, but is expected to be uploaded on the website.

Thursday's decision provides interim relief to several local and multinational drugmakers operating in India's $15 billion drugs industry whose business had been hit by the ban. Many, however, had obtained stay orders days after the ban was announced in March.

The move covered fixed-dose combination drugs, which are cocktails of medicines that are used worldwide to improve patients' compliance in complicated courses of treatment, especially for conditions such as HIV, tuberculosis and malaria.

In India, however, lax regulation and inconsistent enforcement of laws has led to many such drugs entering the market without central approval, a Reuters investigation found last year. Roughly half the drugs sold on the Indian market are combination medicines, including many antibiotics, the misuse of which leads to antibiotic resistance. (http://reut.rs/1J9azFo)

The announced the ban in March saying extensive deliberations with scientific experts had found the medicines lacked therapeutic efficacy. (http://reut.rs/2gKUfo2)

Most companies filed petitions arguing the did not exercise its powers appropriately.

The reversal of the ban means companies can continue to sell these drugs.

The decision is another setback for India's efforts to weed out irrational fixed-dose combination drugs from the market. A similar move in 2007 to ban about 294 such drugs was also met with stiff resistance from the industry, which obtained a stay.

(Writing by Zeba Siddiqui; Editing by Muralikumar Anantharaman)

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard